L D Jacobs
Affiliation: State University of New York at Buffalo
- Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study GroupL D Jacobs
Department of Neurology, State University of New York School of Medicine at Buffalo and Buffalo General Hospital, 14203, USA
N Engl J Med 343:898-904. 2000..Treatment with interferon beta has been shown to help patients with established multiple sclerosis, but it is not known whether initiating treatment at the time of a first clinical demyelinating event is of value...
- Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick
Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, The Cleveland Clinic Foundation, OH 44106, USA
J Neuroimmunol 93:8-14. 1999..The objectives of the current study were to determine: (a) whether CSF abnormalities in MS patients correlated with disease or MRI characteristics, and (b) effects of IFNbeta-1a therapy on these CSF abnormalities...
- Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis ConsortiumB Weinstock-Guttman
William C Baird Multiple Sclerosis Research Center, The Jacobs Neurological Institute, Buffalo, NY 14203, USA
Mult Scler 9:293-8. 2003..Our findings suggest a racial influence in MS. Further genetic studies that consider race differences are warranted to elucidate mechanisms of disease susceptibility...